Please check out the latest Riboscience news

Riboscience ESMO presentation highlights safety, PK, PD and efficacy data from the first 19 patients of the ENPP1 inhibitor RBS2418 Phase 1 study

Riboscience ESMO I/O Presentations Highlight RBS2418 Phase 1 Study Design and the First Human Data From the Evaluation of an ENPP1 Inhibitor for Immune Activation